Protagenic Therapeutics Stock Investor Sentiment

PTIXW Stock  USD 0  0.00  0.00%   
Slightly above 53% of Protagenic Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Protagenic Therapeutics suggests that many traders are impartial. Protagenic Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Protagenic Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
over three weeks ago at news.google.com         
Protagenic Therapeutics adjusts stock option prices By Investing.com - Investing.com South Africa
Google News at Macroaxis
over a month ago at news.google.com         
PTIX stock touches 52-week low at 0.25 amid sharp annual decline - MSN
Google News at Macroaxis
over a month ago at news.google.com         
PTIX stock touches 52-week low at 0.25 amid sharp annual decline - Investing.com
Google News at Macroaxis
over a month ago at news.google.com         
Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split - ACCESS Newswire
Google News at Macroaxis
over two months ago at news.google.com         
PTIX stock touches 52-week low at 0.45 amid market challenges - Investing.com
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Musci Raymond of 100 shares of Protagenic Therapeutics at 1.64 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Protagenic Therapeutics faces Nasdaq delisting over equity deficit - Investing.com
Google News at Macroaxis
over three months ago at investing.com         
Protagenic Therapeutics faces Nasdaq delisting over equity shortfall
Investing News at Macroaxis
over three months ago at news.google.com         
ARMISTICE CAPITAL, LLC Acquires New Stake in Protagenic Therapeu - GuruFocus.com
Google News at Macroaxis
over three months ago at news.google.com         
Protagenic Therapeutics Raises 1.275M for Growth Initiatives - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of 1.275...
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Musci Raymond of 1758 shares of Protagenic Therapeutics at 2.09 subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Acquisition by Musci Raymond of 569 shares of Protagenic Therapeutics at 2.07 subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 75000 shares by Ekizian Gregory of Protagenic Therapeutics at 1.0 subject to Rule 16b...
Macroaxis News
over three months ago at news.google.com         
Short Interest in Protagenic Therapeutics, Inc. Expands By 3,669.0 percent - Defense World
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Protagenic Therapeutics that are available to investors today. That information is available publicly through Protagenic media outlets and privately through word of mouth or via Protagenic internal channels. However, regardless of the origin, that massive amount of Protagenic data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Protagenic Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protagenic Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protagenic Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protagenic Therapeutics alpha.

Protagenic Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.